IMMUNEERING CORP - CLASS A (IMRX) Fundamental Analysis & Valuation

NASDAQ:IMRX • US45254E1073

Current stock price

5.45 USD
+0.12 (+2.25%)
At close:
5.4 USD
-0.05 (-0.92%)
After Hours:

This IMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMRX Profitability Analysis

1.1 Basic Checks

  • IMRX had negative earnings in the past year.
  • In the past year IMRX has reported a negative cash flow from operations.
  • In the past 5 years IMRX always reported negative net income.
  • IMRX had a negative operating cash flow in each of the past 5 years.
IMRX Yearly Net Income VS EBIT VS OCF VS FCFIMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • IMRX has a Return On Assets of -24.15%. This is in the better half of the industry: IMRX outperforms 72.34% of its industry peers.
  • With a decent Return On Equity value of -25.64%, IMRX is doing good in the industry, outperforming 78.34% of the companies in the same industry.
Industry RankSector Rank
ROA -24.15%
ROE -25.64%
ROIC N/A
ROA(3y)-69.7%
ROA(5y)-54.72%
ROE(3y)-84.13%
ROE(5y)-64.35%
ROIC(3y)N/A
ROIC(5y)N/A
IMRX Yearly ROA, ROE, ROICIMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMRX Yearly Profit, Operating, Gross MarginsIMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IMRX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for IMRX has been reduced compared to 1 year ago.
  • IMRX has less shares outstanding than it did 5 years ago.
  • IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMRX Yearly Shares OutstandingIMRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
IMRX Yearly Total Debt VS Total AssetsIMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 13.98 indicates that IMRX is not in any danger for bankruptcy at the moment.
  • IMRX has a better Altman-Z score (13.98) than 85.11% of its industry peers.
  • IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.98
ROIC/WACCN/A
WACCN/A
IMRX Yearly LT Debt VS Equity VS FCFIMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 17.50 indicates that IMRX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 17.50, IMRX belongs to the top of the industry, outperforming 94.78% of the companies in the same industry.
  • A Quick Ratio of 17.50 indicates that IMRX has no problem at all paying its short term obligations.
  • IMRX has a better Quick ratio (17.50) than 94.78% of its industry peers.
Industry RankSector Rank
Current Ratio 17.5
Quick Ratio 17.5
IMRX Yearly Current Assets VS Current LiabilitesIMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IMRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.02% over the past year.
EPS 1Y (TTM)32.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.49% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.94%
EPS Next 2Y-10.38%
EPS Next 3Y-1.77%
EPS Next 5Y9.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRX Yearly Revenue VS EstimatesIMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
IMRX Yearly EPS VS EstimatesIMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMRX Valuation Analysis

4.1 Price/Earnings Ratio

  • IMRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRX Price Earnings VS Forward Price EarningsIMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRX Per share dataIMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.38%
EPS Next 3Y-1.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMRX Dividend Analysis

5.1 Amount

  • IMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMRX Fundamentals: All Metrics, Ratios and Statistics

IMMUNEERING CORP - CLASS A

NASDAQ:IMRX (4/2/2026, 8:00:02 PM)

After market: 5.4 -0.05 (-0.92%)

5.45

+0.12 (+2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06
Earnings (Next)N/A
Inst Owners50.78%
Inst Owner Change17.21%
Ins Owners9.48%
Ins Owner Change1.06%
Market Cap352.34M
Revenue(TTM)N/A
Net Income(TTM)-56.02M
Analysts85
Price Target17.34 (218.17%)
Short Float %21.21%
Short Ratio10.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.32%
Min EPS beat(2)4.96%
Max EPS beat(2)43.68%
EPS beat(4)4
Avg EPS beat(4)18.99%
Min EPS beat(4)4.96%
Max EPS beat(4)43.68%
EPS beat(8)7
Avg EPS beat(8)10.36%
EPS beat(12)10
Avg EPS beat(12)9.93%
EPS beat(16)13
Avg EPS beat(16)9.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.99%
PT rev (3m)0.99%
EPS NQ rev (1m)27.14%
EPS NQ rev (3m)27.14%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.61
P/tB 1.67
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS3.38
TBVpS3.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.15%
ROE -25.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.7%
ROA(5y)-54.72%
ROE(3y)-84.13%
ROE(5y)-64.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.5
Quick Ratio 17.5
Altman-Z 13.98
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)127.9%
Cap/Depr(5y)150.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
EPS Next Y-1.94%
EPS Next 2Y-10.38%
EPS Next 3Y-1.77%
EPS Next 5Y9.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.81%
EBIT Next 3Y-26.85%
EBIT Next 5Y-22.09%
FCF growth 1Y-11.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.32%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNEERING CORP - CLASS A / IMRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IMMUNEERING CORP - CLASS A (IMRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMRX.


What is the valuation status for IMRX stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNEERING CORP - CLASS A (IMRX). This can be considered as Overvalued.


Can you provide the profitability details for IMMUNEERING CORP - CLASS A?

IMMUNEERING CORP - CLASS A (IMRX) has a profitability rating of 1 / 10.


How financially healthy is IMMUNEERING CORP - CLASS A?

The financial health rating of IMMUNEERING CORP - CLASS A (IMRX) is 9 / 10.